42 citations
,
July 2015 in “Drug Development and Industrial Pharmacy” Flutamide, delivered by solid lipid nanoparticles, could potentially treat hair loss.
43 citations
,
December 1993 in “Annals of internal medicine” Flutamide, a medication used for excessive hair growth, can cause severe liver damage in women.
74 citations
,
August 2002 in “Clinical Endocrinology” Flutamide and CPA are more effective than finasteride for treating acne in hyperandrogenic women.
204 citations
,
February 2000 in “Current Medicinal Chemistry” Antiandrogens like flutamide are effective in treating conditions like prostate cancer and hair loss, but there's a need for more potent versions. Understanding their structure can help develop better treatments.
64 citations
,
August 2019 in “Circulation” ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
108 citations
,
January 2003 in “Fertility and Sterility” Flutamide may slightly improve hair loss in women, but finasteride does not work.
53 citations
,
June 1993 in “Proceedings of the National Academy of Sciences of the United States of America” LY191704 is a compound that effectively blocks a specific enzyme involved in hormone conversion and could help treat enlarged prostate and hair loss.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
2 citations
,
January 2011 in “Andrologia” Flutamide and a new synthetic steroid affected brain and prostate chemicals and showed potential for treating androgen-related conditions and epilepsy.
April 2022 in “Reactions Weekly” January 2023 in “International Journal of Trichology” Bicalutamide mesotherapy may help with hair loss and seborrhea but needs more research.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
130 citations
,
September 1990 in “Journal of the American Academy of Dermatology” Flutamide effectively reduced excessive hair growth and improved related symptoms in hirsutism patients without significant side effects.
232 citations
,
June 1975 in “Journal of Steroid Biochemistry” Cyproterone acetate is effective for acne but less so for hirsutism and alopecia, with some side effects and quick menstrual cycle recovery after treatment.
24 citations
,
January 2017 in “International Journal of Trichology”
March 2026 in “Frontiers in Pharmacology” New treatments for hair loss show promise but need more testing for effectiveness and safety.
December 2025 in “IP Indian Journal of Clinical and Experimental Dermatology” Androgenetic alopecia treatments are becoming more personalized and include new therapies like topical antiandrogens and regenerative strategies.
August 2025 in “Fabad Journal of Pharmaceutical Sciences” Bicalutamide effectively treats prostate cancer but needs careful monitoring for side effects.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
17 citations
,
August 2007 in “Bioorganic & Medicinal Chemistry Letters” A compound made by Pfizer can potentially stimulate hair growth and reduce oil production, making it a good candidate for topical use.
39 citations
,
January 1980 in “Dermatology” Cyproterone acetate was effective in treating acne, hirsutism, and alopecia with few side effects.
1 citations
,
January 2013 in “MedChemComm” PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.
October 2021 in “Meditsinskiy sovet = Medical Council” Cyproterone acetate improves skin symptoms and quality of life in women with androgen-related issues.
November 2023 in “Bioorganic Chemistry” Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
December 2023 in “Reactions weekly” January 2023 in “Reactions Weekly” December 2024 in “Reactions Weekly” December 2023 in “Reactions weekly” November 2014 in “Reactions Weekly”